RA
Ranjana H. Advani
Highly rated in
32
conditions

Dr. Ranjana H. Advani

Cancer Immunotherapy Program
Palo Alto, CA
Highly rated in
32
conditions
Specialties:Oncology | Hematology Oncology
Experience:41 Years
Age:66
Clinical Trials:Currently Recruiting for 7 Trials
Accepts:New PatientsMedicare
Highly rated in
32
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

    View 33 More Conditions +
    Check Dr. Ranjana H. Advani's experience treating your condition:
    About Dr. Ranjana H. Advani

    Ranjana Advani is an Oncologist and a Hematologist Oncology expert in Palo Alto, California. Advani has been practicing medicine for over 41 years and is highly rated in 32 conditions, according to our data. Her top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant. She is licensed to treat patients in California. Advani is currently accepting new patients.

    Her clinical research consists of co-authoring 267 peer reviewed articles and participating in 22 clinical trials in the past 15 years.

    Insurance

    MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Ranjana H. Advani it is best to call her office and ask if your insurance is accepted.

    Accepts Medicare

    Dr. Ranjana H. Advani accepts the following insurance:

    •  Ambetter
    Call to see if your plan is accepted.
    Locations
    875 Blake Wilbur Dr, Palo Alto, CA 94304
    Background & Education
    Graduate Institution
    Other, 1982
    Specialties
    Oncology
    Hematology Oncology
    Licenses
    Internal Medicine in CA
    Hospital Affiliations
    Stanford Hospital
    Languages Spoken
    English
    German
    Hindi
    Gender
    Female
    Clinical Research

    Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

    21 Clinical Trials
    A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma
    Enrollment Status: Recruiting
    Publish Date: December 08, 2022
    Intervention Type: Drug, Biological
    Study Drugs: BrentuximabIpilimumabNivolumab
    Study Phase: Phase 1/Phase 2
    A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression
    Enrollment Status: Recruiting
    Publish Date: November 15, 2022
    Intervention Type: Drug
    Study Drugs: Brentuximab vedotinCyclophosphamideDoxorubicinPrednisone
    Study Phase: Phase 2
    A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
    Enrollment Status: Recruiting
    Publish Date: August 26, 2022
    Intervention Type: Drug
    Study Drug: CYT-0851
    Study Phase: Phase 1/Phase 2
    Phase 1/2, Multicenter, First-In-Human, Dose Escalation and Dose Expansion Study of CPO107 Administered Intravenously to Patients With Advanced CD20-positive Non-Hodgkins Lymphoma
    Enrollment Status: Recruiting
    Publish Date: August 10, 2022
    Intervention Type: Drug
    Study Drug: CPO107
    Study Phase: Phase 1/Phase 2
    A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
    Enrollment Status: Recruiting
    Publish Date: June 23, 2022
    Intervention Type: Drug, Procedure
    Study Drugs: MagrolimabPembrolizumab
    Study Phase: Phase 2
    A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
    Enrollment Status: Recruiting
    Publish Date: November 26, 2021
    Intervention Type: Other, Drug, Biological
    Study Drugs: BleomycinBrentuximabDacarbazineDoxorubicinNivolumabVinblastine
    Study Phase: Phase 2
    Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
    Enrollment Status: Recruiting
    Publish Date: July 09, 2020
    Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: December 12, 2022
    Intervention Type: Drug, Biological, Other
    Study Drugs: CyclophosphamideDoxorubicin HydrochlorideLenalidomidePrednisoneRituximabVincristine Sulfate
    Study Phase: Phase 2
    A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab or Rituximab + Chemotherapy in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: December 09, 2022
    Intervention Type: Drug
    Study Drugs: MagrolimabRituximabGemcitabineOxaliplatin
    Study Phase: Phase 1/Phase 2
    A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: December 06, 2022
    Intervention Type: Other, Drug, Biological, Radiation
    Study Drugs: BrentuximabDacarbazineDoxorubicinFilgrastimNivolumabPegfilgrastimVinblastine
    Study Phase: Phase 3
    A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements
    Enrollment Status: Suspended
    Publish Date: November 18, 2022
    Intervention Type: Drug, Biological, Other
    Study Drugs: CyclophosphamideDoxorubicin HydrochlorideOral AzacitidinePrednisoneRituximabVincristine Sulfate
    Study Phase: Phase 2/Phase 3
    A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
    Enrollment Status: Completed
    Publish Date: November 08, 2022
    Intervention Type: Drug, Other, Procedure
    Study Drugs: CyclophosphamideDoxorubicinEtoposideLenalidomidePrednisoneVincristine
    Study Phase: Phase 1/Phase 2
    A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy
    Enrollment Status: Completed
    Publish Date: November 08, 2022
    Intervention Type: Drug
    Study Drugs: BrentuximabNivolumab
    Study Phase: Phase 1/Phase 2
    Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy
    Enrollment Status: Active, not recruiting
    Publish Date: July 22, 2022
    Intervention Type: Drug, Biological
    Study Drugs: BrentuximabNivolumab
    Study Phase: Phase 2
    A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: June 21, 2022
    Intervention Type: Drug, Radiation
    Study Drugs: Anti-Thymocyte GlobulinCyclosporine
    Study Phase: Phase 2
    Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
    Enrollment Status: Completed
    Publish Date: May 11, 2022
    Intervention Type: Drug
    Study Drug: ABT199
    Study Phase: Phase 2
    A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
    Enrollment Status: Active, not recruiting
    Publish Date: March 09, 2022
    Intervention Type: Drug, Biological
    Study Drugs: RituximabBendamustinBortezomibLenalidomide
    Study Phase: Phase 2
    Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
    Enrollment Status: Unknown status
    Publish Date: July 15, 2020
    Intervention Type: Procedure, Drug, Radiation, Other, Biological
    Study Drugs: DacarbazineDoxorubicinPembrolizumabVinblastine18F-Fludeoxyglucose
    Study Phase: Phase 2
    Risk-Adapted Stanford V-C With Radiotherapy for Clinical Stage I and IIA Favorable Hodgkin's Disease: The G5 Study
    Enrollment Status: Completed
    Publish Date: July 24, 2018
    Intervention Type: Drug, Radiation
    Study Phase: Phase 2
    A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
    Enrollment Status: Terminated
    Publish Date: June 21, 2018
    Intervention Type: Drug
    Study Phase: Phase 2
    Phase 2 Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease
    Enrollment Status: Completed
    Publish Date: April 20, 2017
    Intervention Type: Drug
    Study Phase: Phase 2
    View 14 Less Clinical Trials -
    267 Total Publications
    ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas.
    Journal: Clinical lymphoma, myeloma & leukemia
    Published: September 27, 2022
    Save this doctor for later
    Sign Up
    Looking for the best doctor for you?
    Start Here
    Is this your doctor?
    Find a second opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn more
    Similar Doctors
    SP
    Dr. Sukhmani K. Padda
    Hematology Oncology | Oncology
    Highly rated in
    11
    conditions
    Hematology Oncology
    Oncology

    Stanford Health Care

    Thoracic Cancer Program In Palo Alto

    875 Blake Wilbur Dr, 
    Palo Alto, CA 

    Sukhmani Padda is a Hematologist Oncology specialist and an Oncologist in Palo Alto, California. Padda has been practicing medicine for over 16 years and is highly rated in 11 conditions, according to our data. Her top areas of expertise are Thymic Epithelial Tumor, Lung Cancer, Non-Small Cell Lung Cancer (NCSLC), and EGFR Positive Lung Cancer. She is licensed to treat patients in California. Padda is currently accepting new patients.

    YO
    Dr. Yasuhiro Oki
    Hematology Oncology | Hematology | Oncology
    Highly rated in
    29
    conditions
    Hematology Oncology
    Hematology
    Oncology

    Sutter Health

    Valley Medical Oncology Consultants In San Ramon

    5601 Norris Canyon Rd, 
    San Ramon, CA 
     26.5 mi

    Yasuhiro Oki is a Hematologist Oncology specialist and a Hematologist in San Ramon, California. Oki has been practicing medicine for over 25 years and is highly rated in 29 conditions, according to our data. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Texas.

    MK
    Dr. Michael S. Khodadoust
    Oncology | Hematology Oncology
    Highly rated in
    15
    conditions
    Oncology
    Hematology Oncology

    Stanford Health Care

    Brain And Spine Tumor Center At Stanford Cancer Center

    875 Blake Wilbur Dr, 
    Palo Alto, CA 

    Michael Khodadoust is an Oncologist and a Hematologist Oncology expert in Palo Alto, California. Khodadoust has been practicing medicine for over 13 years and is highly rated in 15 conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Peripheral T-Cell Lymphoma, and Bone Marrow Transplant. He is licensed to treat patients in California. Khodadoust is currently accepting new patients.